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Background: There is limited information on the clinical outcomes after utilization of drug-eluting stents for multivessel stenting (MVS) and 
bifurcated lesions. 
Methods: The ARRIVE Program compiled data on 7,492 patients receiving ≥1 TAXUS Express paclitaxel-eluting stent, including patients with MVS 
(n=1,208) and bifurcation stenting (n=575). Patients were enrolled at procedure start with no mandated inclusion/exclusion criteria; all cardiac 
events were monitored with independent adjudication of endpoints. 
Results: Compared to simple-use patients undergoing native coronary intervention (N=2,698), MVS patients had significantly more baseline 
comorbidities. Both groups had higher 2-year rates of mortality (7.5% [MVS] and 7.6% [bifurcation] vs 4.2% [simple-use], P<0.001), myocardial 
infarction (4.5% and 5.0% vs 2.2%, P<0.001), target vessel revascularization (15.5% and 14.8% vs 7.7%, P<0.001), and Academic Research 
Consortium definite/probable stent thrombosis (4.3% and 4.4% vs 1.4%, P<0.001) than the simple-use group (Figure). 
Conclusions: ARRIVE multivessel and bifurcation stenting patients have significantly higher clinical risk through 2 years compared to simple-use 
patients. In the absence of large randomized controlled trials in these populations, ARRIVE provides important insight into clinical outcomes over an 
extended period of time.
